Tavist Sinus, available in August, is first Novartis product launch.
This article was originally published in The Tan Sheet
Executive Summary
NOVARTIS TAVIST SINUS TO HIT SHELVES IN AUGUST as the first offspring of the December 1996 marriage of Ciba and Sandoz. Unlike older siblings Tavist-1 and Tavist-D, Tavist Sinus does not contain clemastine fumarate. Each Tavist Sinus tablet contains 500 mg acetaminophen and 30 mg pseudoephedrine HCl, a familiar monograph combination available in a number of currently marketed OTCs, including McNeil's Sine-Aid and Warner Wellcome's Sinutab.